What can an EVOS microscope be used for?

A comprehensive summary based on published literature

From brain-eating amoebae to tumour-killing immune cells, peer-reviewed papers reveal where EVOS imaging systems are showing up in real labs.

Pick almost any corner of modern biology and there is a decent chance someone, somewhere, has pointed an EVOS microscope at it. The EVOS family — built around brightfield, phase-contrast and fluorescence imaging, often with live-cell and time-lapse capability — has become a workhorse in labs that need publication-quality images without the complexity or price tag of a full confocal suite. But what, exactly, are researchers doing with these instruments? We dug into the peer-reviewed literature to find out.

The result is a picture that is far broader than a single disease or a single technique. EVOS systems appear in studies of cancer, infectious disease, neuroscience, immunology, organoids, tissue engineering, drug discovery and cardiovascular research. They image cells in 2D monolayers, 3D spheroids and patient-derived organoids. They capture fluorescence, brightfield morphology and time-lapse killing assays. And they do so in papers published in journals ranging from Nature Communications and iScience to specialist titles such as Lab on a Chip and STAR Protocols.

Every study mentioned below is drawn from Plankton & Zoom’s verified EVOS publications list. That means each one was opened in full text and checked to confirm that it explicitly names an EVOS model — M5000, M7000, M3000, FL / FL Auto, XL / XL Core — in its methods. If you are weighing up what an EVOS can do for your own UK lab, the buying decision should still start with your sample, your fluorophores and your throughput, which is why our UK microscope buying guide and fluorescence microscope guide are worth a look too. But for now, here is what the published science actually shows.

Cancer and oncology: from tumour spheroids to drug screens

Cancer research is one of the most visible uses of EVOS microscopes in the recent literature. Part of the reason is practical: cancer biologists routinely need to image fluorescent reporters, track spheroid growth and watch immune cells attack tumour cells over time. EVOS systems, particularly the M5000 and M7000 models with their LED light cubes and live-cell chambers, fit those workflows without requiring a darkroom or a dedicated confocal operator.

A good example is the work on natural-killer-cell killing of 3D tumour spheroids, published in PLOS One. The authors built a time-lapse assay to quantify how NK cells destroy tumour spheroids and captured the cytotoxic activity using an EVOS M7000 imaging system. [1] The appeal is obvious: instead of endpoint assays that only tell you whether cells died, time-lapse imaging on an EVOS lets you watch the dynamics of immune attack unfold. That kind of assay is central to immunotherapy research, where understanding the kinetics of cell killing matters as much as the final kill count.

Other cancer studies use EVOS systems for more conventional but no less important fluorescence readouts. Research on colorectal cancer cell lines used an EVOS M5000 to image apoptosis after treatment with plant-derived compounds. [3] A study on lung cancer stem cells used the same platform to assess how a RALGEF inhibitor suppresses stem-cell development and tumorigenesis. [5] Esophageal cancer work imaged epithelial-mesenchymal transition markers, while osteosarcoma studies tracked spheroid formation under treatment with berberine chloride. [2] The common thread is that EVOS imaging provides a fast, reproducible way to turn a pharmacological treatment into a visual, quantifiable cellular response.

Perhaps most striking is the glioblastoma research. Several papers use EVOS systems to image glioblastoma cells, spheroids and organoids, often in combination with gene-editing or drug-screening experiments. One study explored how a fusogenic tandem peptide delivers siRNA into glioblastoma cells; another examined how SYNCRIP drives ferroptosis resistance. [14] [13] In each case the EVOS microscope is the imaging layer that turns molecular manipulation into observable cell behaviour. For labs comparing microscope platforms for cancer research, the message from the literature is clear: EVOS systems are being used wherever fluorescence, morphology and time-lapse need to be combined at benchtop scale.

Infectious disease: amoebae, fungi, bacteria and viruses

If cancer research shows EVOS systems at work in complex cell models, infectious-disease research shows them in some of the most visually dramatic settings of all. The verified literature includes studies of brain-eating amoebae, pathogenic fungi, respiratory viruses, food-borne bacteria and mixed biofilms.

Take Naegleria fowleri, the cause of primary amoebic meningoencephalitis. [7] Multiple independent groups have used EVOS M5000 microscopes to test candidate therapeutics against this deadly parasite. One study evaluated ginsenosides Rb3 and Rc; another tested flucofuron; a third characterised a marine oxasqualenoid called yucatecone. In each case researchers used the EVOS M5000 to capture both visible morphology and fluorescent viability signals at magnifications up to 100×. The parasite is fast-moving and the disease is rare, so the ability to screen compounds quickly with a benchtop fluorescence microscope is genuinely valuable.

Fungal pathogens get similar treatment. A JACS Au paper developed caspofungin-based red-emissive probes for fluorescent imaging of pathogenic fungi and explicitly tested them on a non-confocal EVOS M5000 microscope to demonstrate diagnostic potential in low-resource settings. [8] Candida–Staphylococcus dual biofilms were imaged with a DAPI filter on an EVOS M5000, helping researchers understand heterogeneity and tolerance in mixed infections. A hepatitis-E virus preservation study used EVOS imaging to monitor virus morphology through freeze–thaw cycles. [21]

The virology work is equally varied. Parainfluenza virus type 5 infection was studied by visualising liquid-liquid phase inclusion bodies in infected cells with an EVOS M5000. [9] Other papers image respiratory viruses, SARS-CoV-2 spike variants and adenoviral vectors. What unites them is the need for a simple, rapid way to visualise infected cells, fluorescent reporters or cytopathic effect. An EVOS system, with its integrated camera and LED illumination, sits neatly between a basic tissue-culture microscope and a high-end confocal for this kind of screening work.

Neuroscience and brain disease: neurons, organoids and glioblastoma

The brain is notoriously difficult to image in vitro, yet EVOS systems show up repeatedly in neuroscience papers. The work tends to fall into three categories: neuronal cell culture and differentiation, brain organoids, and glioblastoma.

Neuronal culture studies use EVOS microscopes to validate differentiation protocols. One paper optimised the detection of lipofuscin — an ageing pigment — in cells using an EVOS XL Core. Another compared PANI- and PEDOT:PSS-incorporated GelMA hydrogels for neuronal differentiation of SH-SY5Y cells, using EVOS imaging to assess morphology and neurite outgrowth. [11] A study on NMDA receptors used an EVOS system to image calcium responses in substantia gelatinosa neurons, with implications for pain and sensory processing. [10]

Brain organoids are perhaps the most visually compelling neuroscience application. Quality-control protocols for brain organoid morphology use EVOS XL Core systems to check size, shape and luminal structure before more expensive downstream assays. Early-eye organoid work used EVOS imaging to examine cadherin and semaphorin disruption in PAX6-related aniridia. These studies highlight a practical role for EVOS: as a fast, low-cost checkpoint to make sure organoid cultures are healthy and morphologically normal before committing them to electrophysiology, sequencing or drug screening.

Then there is glioblastoma, the aggressive brain cancer that overlaps with both oncology and neuroscience. Papers on glioblastoma use EVOS systems to image disseminated tumour cells, ferroptosis resistance and peptide-based siRNA delivery. The imaging is not decorative; it is the readout that tells researchers whether their genetic or pharmacological intervention changed cell morphology, viability or invasion.

Immunology and inflammation: watching immune cells in action

Immune cells are transparent, fast and often labelled with multiple fluorescent markers, which makes them a natural fit for LED-based fluorescence microscopes. The EVOS literature includes studies of macrophages, NK cells, neutrophils, T cells and monocytes in contexts ranging from cancer to infection to autoimmune disease.

The NK-cell spheroid-killing assay mentioned earlier is a flagship example. By quantifying time-lapse 3D tumour spheroid killing activity, researchers can compare how different treatments boost or suppress immune-cell cytotoxicity. Macrophage research is equally well represented. One paper examined how low-intensity pulsed ultrasound regulates mitophagy in endothelial cells; another studied SIRPα/CD47 disruption to enhance macrophage phagocytosis of cancer cells. The desmosomal cadherin Desmoglein-2 was imaged in keratinocytes to understand extracellular-matrix remodelling via NF-κB.

What these papers share is the need to combine fluorescent markers with morphology in a way that is fast enough for medium-throughput experiments. An EVOS M7000 with its automated stage and live-cell chamber can image multi-well plates of immune cells overnight, producing the kind of time-resolved data that flow cytometry alone cannot capture. For labs building automated cell-counting or immune-assay workflows, this literature is a useful signpost.

Organoids, spheroids and tissue engineering

Three-dimensional cell models have transformed how researchers study development, disease and drug response. EVOS microscopes appear throughout this literature because they can image spheroids and organoids in brightfield or fluorescence without the sectioning required by confocal microscopy.

Liver progenitor organoids were imaged on an EVOS M5000 at low magnification to track differentiation towards a hepatocyte lineage, in work on fibrolamellar carcinoma. Patient-derived kidney organoids modelling autosomal-dominant polycystic kidney disease used an EVOS M7000 as part of a screening pipeline that identified Rho-pathway inhibitors as candidate therapeutics. Brain and eye organoids, as already noted, use EVOS imaging for routine quality control.

Tissue-engineering papers extend the theme into biomaterials. Aligned polyhydroxybutyrate fibrous scaffolds, made via a touchspinning apparatus, were imaged with an EVOS M5000 at 20× after cell seeding. A BAI1-PSTB hydrogel for diabetic wound healing was assessed with EVOS imaging. [19] Extracellular vesicles from melanoma-associated fibroblasts, captured on an EVOS XL Core, were studied for their ability to prime brain microvascular cells ahead of metastasis. [20]

The takeaway is that EVOS systems are being used not just to look at cells, but to look at cells inside increasingly complex environments: hydrogels, scaffolds, spheroids and organoids. That makes them relevant to anyone moving from traditional 2D cell culture towards more physiologically realistic models.

Cardiovascular, metabolic and wound-healing research

The EVOS literature also reaches into cardiovascular biology, metabolic disease and wound repair. Endothelial cells are a recurring subject, which makes sense: they are thin, fluorescent-label friendly, and central to vascular biology, atherosclerosis and blood–brain-barrier research.

One study used an EVOS M7000 to image endothelial cells and explore how hypotonic stimuli promote osteocyte dendrite formation via actin dynamics. Another examined lack of oxygen and glucose in cerebral endothelial cells, with implications for stroke and Alzheimer’s disease. [12] Cationic peptoids for in-vivo cartilage targeting were validated with EVOS imaging. Robinin, a natural compound, was shown to attenuate cardiac oxidative-stress-induced apoptosis, with EVOS imaging supporting the cellular readouts.

Metabolic disease appears through adipocyte differentiation, obesity-related neural stem-cell stress and diabetes models. Wound-healing studies use EVOS systems to image fibroblasts, keratinocytes and endothelial cells inside hydrogels or on scaffolds. The unifying idea is that EVOS imaging provides a quick, affordable way to quantify cellular responses in disease-relevant cell types before moving to animal models or human samples.

Drug discovery and high-throughput screening

Many of the papers above are, at heart, drug-discovery studies. Whether the target is cancer, infection or neurodegeneration, researchers need a way to see whether a compound changed cell behaviour. EVOS systems are repeatedly used as that visual layer.

Examples include high-throughput screening of small molecules against Mycobacterium tuberculosis, phenotypic profiling of acute lymphoblastic leukaemia cells, and competitive-fitness assays in yeast using high-throughput fluorescence microscopy. The droplet-digital microfluidics paper used an EVOS M5000 to image single sorted cells in well plates, bridging microfluidics and conventional plate imaging.

The practical advantage here is throughput. A benchtop EVOS with a multi-well plate holder and automated stage can image dozens to hundreds of fields per hour, producing the kind of quantitative imaging data that drug-discovery teams need. It is not a high-content screening platform in the CellInsight sense, but for many academic and small-biotech labs it sits in a sweet spot of capability and accessibility.

What makes EVOS suitable across so many fields?

Reading through the literature, a few practical themes emerge. First, EVOS systems are integrated: camera, LED illumination, filters and software are built into a single benchtop unit. That lowers the barrier to entry for labs that do not have a dedicated microscopy room or a full-time imaging specialist. Second, the LED light cubes cover standard fluorescent dyes, so GFP, RFP and DAPI are all straightforward. Third, the systems handle both brightfield and fluorescence, making them useful for routine cell-culture checks as well as experimental imaging.

The M5000 and M7000 models appear most often in the recent literature, with the M7000 adding automated stage and live-cell capabilities that suit time-lapse and multi-well work. Older EVOS FL and XL / XL Core systems still appear in a large fraction of papers, reflecting the long working life of these instruments in academic labs. The newer M3000 and S1000 are less represented in the open-access literature so far, simply because they are newer platforms and fewer papers have been published using them.

None of this means an EVOS is the right microscope for every experiment. High-resolution subcellular imaging, deep-tissue imaging or super-resolution microscopy still require more specialised instruments. But for the bread-and-butter work of modern cell biology — imaging fluorescently labelled cells, tracking organoids, watching immune cells kill targets, screening compounds — the peer-reviewed literature shows that EVOS systems are a genuinely credible choice.

The bottom line

The published literature paints EVOS microscopes as flexible, widely adopted imaging tools for cell biology. They appear in cancer, infectious disease, neuroscience, immunology, organoid research, tissue engineering, cardiovascular and metabolic studies, and drug discovery. They image 2D cultures, 3D spheroids, organoids, scaffolds and hydrogels. They capture brightfield, fluorescence and time-lapse data. And they do so in studies that are independently peer-reviewed and openly accessible.

If you want to see the raw evidence — every paper, its EVOS model, the exact quote from its methods, and links to PubMed, PMC and the publisher DOI — visit our verified EVOS publications page. For help choosing a microscope for your own UK research, start with our UK microscope buying guide or microscopes overview. The science is clear: whatever your cell model, there is probably an EVOS paper out there doing something close to it.

References

Citations below are formatted in Vancouver style. Each entry links to PubMed, PubMed Central or the publisher DOI. The instrument attribution for each paper is verified against the open-access full text.

1. Srisantitham J, Thongsin N, Suwanpitak S, Wattanapanitch M. Quantification of timelapse 3D tumor spheroid killing activity of NK cells using a live-cell imaging system. PLoS One. 2025. doi:10.1371/journal.pone.0334246.

2. Jeong M, Seo J, Park S, Ham J. Berberine Chloride Suppresses Growth of Canine Osteosarcoma Cells via Regulating MMP2/AKT/β-Catenin Pathway. Antioxidants (Basel). 2026. doi:10.3390/antiox15091094.

3. Calvello R, Cianciulli A, Compierchio A, Porro C, Caponio GR, De Angelis M, Panaro MA. Phenolic-Rich Extracts from Artichoke By-Products Promote Apoptosis in Human Colorectal Cancer Cell Lines. Nutrients. 2026. doi:10.3390/nu18132077.

4. Lima LJ, Lohan-Codeço M, Barambo Wagner ML, Paiva Ramos de Oliveira I, Adade ARM, Ribeiro Tomé LM, Meireles Da Costa N, Ribeiro Pinto LF, Nasciutti LE, Ramundo MS, Palumbo A. Inhibition of the AT-Hook DNA-Binding Domain Attenuates HMGA2-Mediated Epithelial Mesenchyme Transition in Esophageal Cancer Cells. Int J Mol Sci. 2026. doi:10.3390/ijms27156933.

5. Jigo R, Clark GJ. A RALGEF inhibitor suppresses lung cancer stem cell development and tumorigenesis. J Biol Chem. 2026. doi:10.1016/j.jbc.2026.113564.

6. Harper D, Shapovalov I, Cockburn S, Aaron A, Gao Y, Greer PA. Genetic disruption of Capns1 impairs metastatic phenotypes in murine mammary carcinoma cells. MicroPubl Biol. 2026. doi:10.17912/micropub.biology.002124.

7. Nguyễn TH, Lê HG, Võ TC, Cho M, Na BK. Ginsenosides Rb3 and Rc Exhibit Anti-Amoebic Activities Against Naegleria fowleri, the Etiological Agent of Primary Amoebic Meningoencephalitis. Pharmaceuticals (Basel). 2026. doi:10.3390/ph19040573.

8. Klausen M, Sharma R, Brown JL, Ramage G, Bradley M. Caspofungin-Based Red-Emissive Probes for Fluorescent Imaging of Pathogenic Fungi. JACS Au. 2026. doi:10.1021/jacsau.6c00209.

9. Wignall-Fleming EB, Carlos TS, Randall RE. Liquid-liquid phase inclusion bodies in acute and persistent parainfluenaza virus type 5 infections. J Gen Virol. 2024. doi:10.1099/jgv.0.002021.

10. Tran TQN, Park SA, Jang SH, Jung W, Han SK. Aloin attenuates NMDA receptor by modulating calcium response on substantia gelatinosa neurons of the trigeminal subnucleus caudalis in mice. Korean J Physiol Pharmacol. 2026. doi:10.4196/kjpp.25.317.

11. Pyo G, Yu HS, Kang Y, Lee H, Lee HJ. Comparison of PANI- and PEDOT:PSS-Incorporated GelMA Hydrogels for Neuronal Differentiation of SH-SY5Y Cells. Gels. 2026. doi:10.3390/gels12100892.

12. Carey A, Buzhdygan T, Fossati S. Lack of Oxygen and/or Glucose Differentially Potentiates Aβ40e22q- and Aβ42-Induced Cerebral Endothelial Cell Death, Barrier Dysfunction and Angiogenesis Impairment. Cells. 2026. doi:10.3390/cells15050424.

13. Boulos JR, Russi KE, Kinnitt J, Gomez Escudero D, Willis T, Abadeer J, Mann E, Anderson AC, Alexander-Bryant A. An EGFR-Targeted Fusogenic Tandem Peptide for siRNA Delivery in Glioblastoma. Pharmaceutics. 2026. doi:10.3390/pharmaceutics18091086.

14. Kim HJ, Song HJ, Kim YG, Kang M, Kim TJ, Byun JS, Kim DY. SYNCRIP drives ferroptosis resistance and metabolic activation via SIRT1 and HK2 in glioblastoma. Int J Biol Sci. 2026. doi:10.7150/ijbs.127096.

15. DiPietro E, Bharath N, Karski M, Durfee O, Sherman MS, Ma Q, Sun L, Farghli AR, Smith CJ, Kycia I, Sethupathy P, Goessling W, Rogers MS, Vakili K. Expression of DNAJB1-PRKACA oncogene suppresses the differentiation potential of liver progenitor organoids towards a hepatocyte lineage. Sci Rep. 2025. doi:10.1038/s41598-025-11028-4.

16. Guo L, Fan Y, Sun H, Du H, Xiong H, Li Y, Zhang X, Guan Y, Ren L, Wang X, Chen K, An Y, Zhang X, Mao Y, Gong Y, Kong F, Qiu J, Chen R, Shi B, Yi F, Hu H, Zhao S. Patient-derived kidney organoids recapitulate ADPKD and facilitate the identification of Rho pathway inhibitors as candidate therapeutics. Cell Rep Med. 2026. doi:10.1016/j.xcrm.2026.102720.

17. Chiaradia I, Boulanger J, Elmkvist SB, Larsen MR, Lancaster MA. Protocol for quality control screening of brain organoid morphology. STAR Protoc. 2026. doi:10.1016/j.xpro.2026.104423.

18. Cronbach N, Justynska G, Méjécase C, Harding P, Eintracht J, Boot J, Berg E, Lima Cunha D, Moosajee M. Early Eye Organoids Demonstrate Cadherin and Semaphorin Disruption in PAX6-Related Aniridia. Int J Mol Sci. 2026. doi:10.3390/ijms27198449.

19. Wang X, Zheng R, Cheng W, Xu Y, Xu XJ, Fu H, Wu D, Wang P, Zhang Y, Wu H, Chen J, Zhao P, Liu S, Liang X, Yin W, Shen K, Li J. A BAI1-PSTB-Hydrogel promotes diabetic wound healing by targeting mtDNA leakage and the cGAS-STING axis to alleviate endothelial senescence. Bioact Mater. 2026. doi:10.1016/j.bioactmat.2026.05.024.

20. Shelton M, Anene CA, Nsengimana J, Eldahshoury MK, Gillet-Woodley JG, Keane B, Roberts W, Newton-Bishop J, Boyne JR. Extracellular Vesicles From a Model of Melanoma Cancer-Associated Fibroblasts Induce Changes in Brain Microvascular Cells Consistent With Pre-Metastatic Niche Priming. J Extracell Biol. 2025. doi:10.1002/jex2.70094.

21. Jiao Z, Feng Z. Optimized Buffer for Preservation of Hepatitis E Virus During Freeze-Thaw Cycles. Bio Protoc. 2026. doi:10.21769/bioprotoc.5781.

22. Stein P, Emori C, Padilla-Banks E, Radonova L, Gruzdev A, Ikawa M, Williams CJ. Beware of your "oocyte specific" Cre line: somatic cell Cre expression in several Zp3-Cre lines and the Gdf9-iCre transgenic line†. Biol Reprod. 2026. doi:10.1093/biolre/ioag093.

23. Wang X, Li L, Song F. Measuring Laplace pressure and imaging the actin cortex during cytokinesis in cultured cells. STAR Protoc. 2022. doi:10.1016/j.xpro.2022.101239.

24. Lukacheva AV, Zinovyeva AS, Kuzmin AA, Gordeev MN, Vasilin VV, Kriger DV, Aksenov ND, Tomilin AN, Bakhmet EI. Oct4 Contributes to Mesodermal Differentiation by Sustaining the Proliferative Capacity of Early Mesodermal Progenitors. Int J Mol Sci. 2025. doi:10.3390/ijms27010054.

Frequently asked questions

Browse the verified EVOS publications →